Investor Presentaiton
53
Investor presentation
Full year 2022
ONWARDS 1 met its primary endpoint and demonstrated
superior HbA1c reduction compared to insulin glargine U100
Superior change in HbA1c from baseline over time 52 weeks
Time since randomisation (weeks)
•
Inclusion criteria
T2D treated with OADs* + GLP-1 s.c.
10
18
0.0
-0.4
-0.8
Change from baseline (%)
-1.2
26
36
46
52
52*
•
Age ≥ 18 years, HbA1c 7.0-11.0%, BMI ≤ 40 kg/m²
H
Κ
KH
HH
Novo NordiskⓇ
Endpoints:
Once-weekly insulin icodec achieved a superior reduction in
estimated HbA1c of -1.55% compared to -1.35% for insulin
glargine U100 (ETD:-0.19%)
Superior time in range for insulin icodec vs insulin glargine U100
broadly equal to one additional hour in range per day
-1.35%
Safety:
-1.55%
-1.6
-2.0
Once-weekly insulin icodec
Note: Overall baseline HbA1c of 8.5%
Once-daily insulin glargine U100
No statistically significant difference in estimated rates of severe
or clinically significant hypoglycaemia events
Insulin icodec appeared to have a safe and well-tolerated profile
*Lines are based on observed data where the value denoted after 52 weeks is estimated mean value derived based on multiple imputation
ETD: Estimate treatment differenceView entire presentation